graph Evidence gap map comparisons
anti-CTLA-4nivolumab based treatmentanti-PD-(L)1Immune checkpoint association
tremelimumab nivolumab alone nivolumab followed by ipilimumab nivolumab plus ipilimumab relatlimab plus nivolumab
mML - L1 - all population 7            
Comparator:  vs ipilimumab alone;   vs ipilimumab followed by nivolumab;   vs nivolumab alone;   vs Standard of Care (SoC); 
Risk of bias:  low;   some concerns;   high;  NA;